NEUCA S.A.
Research NEUCA S.A. (7HD) on Bullrun: valuation model: 4.2% undervalued, market cap EUR 720.97M, P/E 17.8, dividend yield 2.6%. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- Ticker7HD
- ExchangeF
- CountryPoland
- SectorHealthcare
- IndustryMedical Distribution
- CurrencyEUR
- Valuation signal4.2% undervalued
- Market capEUR 720.97M
- P/E17.8
- Dividend yield2.6%
- Financial periodFY2022
- RevenuePLN 11.23B
- Revenue growth13.9%
- Net incomePLN 147.59M
- Gross margin11.1%
Valuation Snapshot
Bullrun's latest valuation model marks NEUCA S.A. as 4.2% undervalued; latest market cap is EUR 720.97M; P/E is 17.8; dividend yield is 2.6%.
About NEUCA S.A.
NEUCA S.A. engages in the wholesale distribution of pharmaceuticals in Poland. It operates through Wholesale Distribution of Medicines, Manufacture of Pharmaceuticals, Medical Operator, Clinical Trials, and Insurance Activities segments. The company offers Rx, OTC drugs, dietary supplements, medical devices, dermocosmetics, hygiene products, personal protective equipment, as well as diagnostic and dressing materials under the Swiat Zdrowia, APTEO, GENOPTIM, CERA+ Solutions, and Kic Kic brands.
Frequently asked questions
Is NEUCA S.A. overvalued or undervalued?
Bullrun's valuation model currently marks NEUCA S.A. as 4.2% undervalued.
What is NEUCA S.A.'s market cap?
NEUCA S.A.'s market capitalization is EUR 720.97M.
What is NEUCA S.A.'s P/E ratio?
NEUCA S.A.'s price-to-earnings (P/E) ratio is 17.8.
Does NEUCA S.A. pay a dividend?
NEUCA S.A. has a dividend yield of 2.6%.
What does NEUCA S.A. do?
NEUCA S.A. engages in the wholesale distribution of pharmaceuticals in Poland. It operates through Wholesale Distribution of Medicines, Manufacture of Pharmaceuticals, Medical Operator, Clinical Trials, and Insurance Activities segments.